Publication at First Faculty of Medicine |
2016
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease characterised by reduced number of thrombocytes with increased risk of bleeding or actual bleeding, depending on the degree of thrombocytopenia. Over recent years, there was a shift in the way we view the pathophysiology of ITP, accompanied by a change in terminology and classification, and new therapeutic options have been introduced.
The objective of the present article is to provide a summary of the prevailing views of the therapy of ITP in adults.